A detailed history of Cutler Group LP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Cutler Group LP holds 440 shares of ASND stock, worth $61,067. This represents 0.02% of its overall portfolio holdings.

Number of Shares
440
Holding current value
$61,067
% of portfolio
0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 19, 2024

BUY
$123.45 - $159.4 $54,318 - $70,136
440 New
440 $66,000
Q3 2023

Nov 07, 2023

SELL
$86.5 - $103.97 $39,790 - $47,826
-460 Reduced 69.7%
200 $18,000
Q2 2023

Jul 18, 2023

BUY
$69.96 - $97.84 $35,679 - $49,898
510 Added 340.0%
660 $58,000
Q1 2023

May 01, 2023

SELL
$104.9 - $126.78 $5,245 - $6,339
-50 Reduced 25.0%
150 $16,000
Q4 2022

Feb 07, 2023

BUY
$99.42 - $131.97 $19,884 - $26,394
200 New
200 $24,000
Q2 2022

Aug 04, 2022

SELL
$78.08 - $117.61 $615,504 - $927,119
-7,883 Reduced 81.65%
1,772 $164,000
Q1 2022

Apr 14, 2022

BUY
$102.18 - $135.75 $986,547 - $1.31 Million
9,655 New
9,655 $1.13 Million
Q4 2021

Jan 18, 2022

SELL
$127.1 - $169.66 $19,065 - $25,449
-150 Closed
0 $0
Q3 2021

Oct 26, 2021

SELL
$112.67 - $176.92 $30,420 - $47,768
-270 Reduced 64.29%
150 $23,000
Q3 2020

Oct 27, 2020

SELL
$134.29 - $154.32 $212,178 - $243,825
-1,580 Reduced 79.0%
420 $64,000
Q1 2020

May 07, 2020

BUY
$97.01 - $145.11 $77,608 - $116,088
800 Added 66.67%
2,000 $225,000
Q4 2018

Feb 05, 2019

BUY
$55.16 - $69.67 $22,064 - $27,868
400 Added 50.0%
1,200 $75,000
Q2 2018

Aug 10, 2018

BUY
$58.55 - $73.92 $46,840 - $59,136
800 New
800 $53,000

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.75B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.